Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial

Oncology Reports

Volumn 28, Issue 4, 2012, Pages 1131-1138

  Oshita, Chie ^a   Takikawa, Masako ^a   Kume, Akiko ^a   Miyata, Haruo ^a   Ashizawa, Tadashi ^a   Iizuka, Akira ^a   Kiyohara, Yoshio ^a   Yoshikawa, Shusuke ^a   Tanosaki, Ryuji ^b   Yamazaki, Naoya ^b   Yamamoto, Akifumi ^c   Takesako, Kazutoh ^d   Yamaguchi, Ken ^a   Akiyama, Yasuto ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d TAKARA BIO INC   (Japan)

Author keywords

Dendritic cell; HLA A24; Immunotherapy; Metastatic melanoma; Overall survival

Indexed keywords

CD83 ANTIGEN; DENDRITIC CELL VACCINE; HLA A2 ANTIGEN; HLA A24 ANTIGEN; KEYHOLE LIMPET HEMOCYANIN; MELAN A; MELANOCYTE PROTEIN PMEL 17; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HLA TYPING; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LIVER DISEASE; MALE; METASTATIC MELANOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME; VACCINATION;

AGED; ANTIGENS, NEOPLASM; AUTOANTIBODIES; CANCER VACCINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEMOCYANIN; HLA-A2 ANTIGEN; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MART-1 ANTIGEN; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VACCINATION;

EID: 84866458433     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1956     Document Type: Article

References (33)

1. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM and Deleo AB: Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat Med 1: 1297-1302, 1995.
2. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT and Storkus WJ: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183: 87-97, 1996. (Pubitemid 26028748)
3. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998. (Pubitemid 28144092)
4. Ranieri E, Kierstead LS, Zarour H, Kirkwood JM, Lotze MT, Whiteside T and Storkus WJ: Dendritic cell/peptide cancer vaccine: clinical responsiveness and epitope spreading. Immunol Invest 29: 121-125, 2000. (Pubitemid 30316952)
5. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, et al: Vaccination with Mage-3a1 peptide-pulsed mature, monocyte- derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190: 1669-1678, 1999. (Pubitemid 30002348)
6. Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA and Marincola FM: Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 23: 487-498, 2000. (Pubitemid 30457707)
7. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, Kandemir A, Lee PP, Schuler G, Knop J and Enk AH: A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93: 243-251, 2001. (Pubitemid 32574281)
8. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, et al: Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res 61: 6451-6458, 2001. (Pubitemid 32783251)
9. Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, Ryback ME and Weber J: Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24: 66-78, 2001. (Pubitemid 32103309)
10. Chakraborty NG, Sporn JR, Tortora AF, Kurtzman SH, Yamase H, Ergin MT and Mukherji B: Immunization with a tumor-cell-lysate- loaded autologous-antigen- presenting-cell-based vaccine in melanoma. Cancer Immunol Immunother 47: 58-64, 1998. (Pubitemid 28430531)
11. Smithers M, O'Connell K, MacFadyen S, Chambers M, Greenwood K, Boyce A, Abdul-Jabbar I, Barker K, Grimmett K, Walpole E and Thomas R: Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol Immunother 52: 41-52, 2003. (Pubitemid 36177225)
12. Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, Geiger JD and Mule JJ: A phase I trial of tumor-lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8: 1021-1032, 2002. (Pubitemid 35177351)
13. Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH and Vuk-Pavlovic S: Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate camcer: a Phase 2 trial. Prostate 60: 197-204, 2004. (Pubitemid 38971831)
14. Cheever MA and Higano CS: PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 17: 3520-3526, 2011.
15. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al; IMPACT Study Investigators: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422, 2010.
16. Akiyama Y, Tanosaki R, Inoue N, Shimada M, Hotate Y, Yamamoto A, Yamazaki N, Kawashima I, Nukaya I, Takesako K, et al: Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J Transl Med 3: 4, 2005.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
18. Iizuka A, Komiyama M, Tai S, Oshita C, Kurusu A, Kume A, Ozawa K, Nakamuya Y, Ashizawa T, Yamamoto A, et al: Identification of cytomegalovirus (CMV) pp65 antigen-specific human monoclonal antibodies using single B cell-based antibody gene cloning from melanoma partients. Immunol Lett 135: 64-73, 2011.
19. Hersey P, Menzies SW, Halliday GM, Nguyen T, Farrelly ML, DeSilva C and Lett M: Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 53: 125-134, 2004. (Pubitemid 38161219)
20. Desmetz C, Maudelonde T, Mange A and Solassol J: Identifying autoantibody signature in cancer: a promising challenge. Expert Rev Proteomics 6: 377-386, 2009.
21. Desmetz C, Cortijo C, Mange A and Solassol J: Humoral response to cancer as a tool for biomarker discovery. J Proteomics 72: 982-988, 2009.
22. Tan HT, Low J, Lim SG and Chung MC: Serum autoantibodies as biomarkers for early cancer detection. FEBS J 276: 6880-6904, 2009.
23. Liu Y, He J, Xie X, Su G, Teitz-Tennenbaum S, Sabel MS and Lubman DM: Serum autoantibody profiling using a natural glycoprotein microarray for the prognosis of early melanoma. J Proteome Res 9: 6044-6051, 2010.
24. Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A and Old LJ: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187: 1349-1354, 1998. (Pubitemid 28189124)
25. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pages F and Galon J: Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res 71: 1263-1271, 2011.
26. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964, 2006. (Pubitemid 44498003)
27. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, et al: Long-term survival for patients with non-small cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26: 4410-4417, 2008.
28. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM and Small EJ: Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 107: 67-74, 2006. (Pubitemid 43939032)
29. Cheever MA: Twelve immunotherapy drugs that could cure cancers. Immunol Rev 222: 357-368, 2008. (Pubitemid 351430366)
30. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, et al; Prostate Cancer Clinical Trials Working Group: Design amd end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: 1148-1159, 2008.
31. Buonerba C, Ferro M and Di Lorenzo G: Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Expert Rev Anticancer Ther 11: 25-28, 2011.
32. Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H and Hoos A: Lessons from randomized phase III studies with active cancer immunotherapies-outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccines 25 (Suppl 2): S97-S109, 2007.
33. Tyagi P and Mirakhur B: MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 10: 371-374, 2009.